These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 24198244)
1. Tumor microenvironment-released peptides: could they form the basis for an early-diagnosis breast cancer test? Diamandis EP Clin Chem; 2014 Jan; 60(1):4-6. PubMed ID: 24198244 [No Abstract] [Full Text] [Related]
2. [Diagnostic value of combined detection of TPS, CA153 and CEA in breast cancer]. Zheng H; Luo RC Di Yi Jun Yi Da Xue Xue Bao; 2005 Oct; 25(10):1293-4, 1298. PubMed ID: 16234113 [TBL] [Abstract][Full Text] [Related]
3. CA 15.3, CEA and TPA tumor markers in the early diagnosis of breast cancer relapse. Vizcarra E; Lluch A; Cibrián R; Jarque F; García-Conde J Oncology; 1994; 51(6):491-6. PubMed ID: 7970492 [TBL] [Abstract][Full Text] [Related]
4. Determination of serum tumor markers TPS and CA 15-3 during monitoring of treatment in metastatic breast cancer patients. Schuurman JJ; Bong SB; Einarsson R Anticancer Res; 1996; 16(4B):2169-72. PubMed ID: 8694538 [TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of measuring serum CA 15-3, TPA, and TPS in women with breast cancer. Sliwowska I; Kopczyński Z; Grodecka-Gazdecka S Postepy Hig Med Dosw (Online); 2006; 60():295-9. PubMed ID: 16767053 [TBL] [Abstract][Full Text] [Related]
6. TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients. Giai M; Roagna R; Ponzone R; Biglia N; Sgro L; Perona M; Sismondi P Anticancer Res; 1996; 16(2):875-81. PubMed ID: 8687144 [TBL] [Abstract][Full Text] [Related]
7. [Clinical value of CA 15-3 for early detection of relapse in locally advanced breast cancer]. Konan S; Goussot V; Desmoulins I; Lorgis V; Coutant C; Fumoleau P; Beltjens F; Dalban C; Lizard S; Riedinger JM Bull Cancer; 2015 Oct; 102(10):834-44. PubMed ID: 26422277 [TBL] [Abstract][Full Text] [Related]
8. Use of serum tumor markers for the diagnosis and follow-up of breast cancer. Barrenetxea G; Schneider J; Llorente MF Oncology; 1998; 55(5):447-9. PubMed ID: 9732223 [No Abstract] [Full Text] [Related]
9. Serum tissue polypeptide specific antigen (TPS) in breast cancer patients: comparison with CA 15.3 and CEA. Willsher PC; Beaver J; Blamey RW; Robertson JF Anticancer Res; 1995; 15(4):1609-11. PubMed ID: 7654057 [TBL] [Abstract][Full Text] [Related]
10. Serum tumour markers CEA, AFP, CA 15-3, TPS and Neu in diagnosis of breast cancer. Eskelinen M; Kataja V; Hämäläinen E; Kosma VM; Penttilä I; Alhava E Anticancer Res; 1997; 17(2B):1231-4. PubMed ID: 9137478 [TBL] [Abstract][Full Text] [Related]
11. [CEA and early detection of relapse in breast cancer subtypes: Comparison with CA 15-3]. Riedinger JM; Goussot V; Desmoulins I; Lorgis V; Coutant C; Beltjens F; Lizard S; Fumoleau P Bull Cancer; 2016 May; 103(5):434-43. PubMed ID: 26969424 [TBL] [Abstract][Full Text] [Related]
12. Tumor markers: should we or shouldn't we? McCarthy NJ; Swain SM Cancer J; 2001; 7(3):175-7. PubMed ID: 11419024 [No Abstract] [Full Text] [Related]
13. [Tumor markers in breast cancer]. Kurebayashi J Gan To Kagaku Ryoho; 2004 Nov; 31(12):2077-81. PubMed ID: 15570944 [TBL] [Abstract][Full Text] [Related]
16. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer. Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854 [TBL] [Abstract][Full Text] [Related]
17. [Tumor markers in breast cancer]. Inaji H; Komoike Y; Motomura K; Koyama H Nihon Rinsho; 2000 Apr; 58 Suppl():140-5. PubMed ID: 11025987 [No Abstract] [Full Text] [Related]
18. Serological tumor markers for monitoring breast cancer. Sölétormos G Dan Med Bull; 2001 Nov; 48(4):229-55. PubMed ID: 11767127 [No Abstract] [Full Text] [Related]